Abstract:INTRODUCTION: This study is to evaluate the safety and pharmacokinetics (PK) of larsucosterol (DUR-928 or 25HC3S) in subjects with alcohol-associated hepatitis (AH), a devastating acute illness without US Food and Drug Administration–approved therapies. METHODS: This phase 2a, multicenter, open-label, dose escalation study evaluated the safety, PK, and efficacy signals of larsucosterol in 19 clinically diagnosed subjects with AH. Based on the model for end-stage liver disease (MELD) score, 7 subjects were considered to have moderate AH and 12 to have severe AH. All subjects received 1 or 2 intravenous infusions (72 hours apart) of larsucosterol at a dose of 30, 90, or 150 mg and were followed up for 28 days. Efficacy signals from a subgroup of subjects with severe AH were compared with those from 2 matched arms of those with severe AH treated with standard of care (SOC), including corticosteroids, from a contemporaneous study. RESULTS: All 19 larsucosterol-treated subjects survived the 28-day study. Fourteen (74%) of all subjects including 8 (67%) of the subjects with severe AH were discharged ≤72 hours after receiving a single infusion. There were no drug-related serious adverse events nor early terminations due to the treatment. PK profiles were not affected by disease severity. Biochemical parameters improved in most subjects. Serum bilirubin levels declined notably from baseline to day 7 and day 28, and MELD scores were reduced at day 28. The efficacy signals compared favorably with those from 2 matched groups treated with SOC. Lille scores at day 7 were <0.45 in 16 of the 18 (89%) subjects with day 7 samples. Lille scores from 8 subjects with severe AH who received 30 or 90 mg larsucosterol (doses used in phase 2b trial) were statistically significantly lower (P < 0.01) than those from subjects with severe AH treated with SOC from the contemporaneous study. DISCUSSION: Larsucosterol was well tolerated at all 3 doses in subjects with AH without safety concerns. Data from this pilot study showed promising efficacy signals in subjects with AH. Larsucosterol is being evaluated in a phase 2b multicenter, randomized, double-blinded, placebo-controlled (AHFIRM) trial.

Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis: Current Status and Future Landscape

Emerging Pharmacotherapies in Alcohol-Associated Hepatitis

Current and future treatment for alcoholic‐related liver diseases

Alcoholic hepatitis: Translational approaches to develop targeted therapies

Current Medical Treatment for Alcohol-Associated Liver Disease

Pharmacotherapy of alcoholic liver disease in clinical practice

New Drug Targets for Alcoholic Liver Disease

Alcoholic liver injury: pathogenesis and therapy in 2001

T1864 Early Mortality of Alcoholic Hepatitis: A Review of Data from Placebo-Controlled Clinical Trials

Alcoholic Hepatitis: A Review

Nutritional and microbiota-based therapeutic intervention for alcohol-associated liver disease: Pathogenesis to therapeutic insights

Early mortality of alcoholic hepatitis: a review of data from placebo-controlled clinical trials.

Alcoholic hepatitis: diagnosis and management in 2012

Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options

Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy

Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease

S1870 Fecal Microbiota Transplantation: A Potential Game Changer for Severe Alcoholic Hepatitis? A Systematic Review and Meta-Analysis

Preclinical Hepatoprotective Effect of Herbalism Against Ethanol Induced Hepatotoxicity: A Review

Efficacy of prophylactic antibiotics in the adjuvant treatment of alcohol-related liver disease (ALD): A systematic review and meta-analysisProphylactic antibiotics in ALD

Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis